Business Wire

NOVALIQ Strengthens Executive Management Team with the Appointment of Gabriela Burian, MD, MPH, as Chief Medical Officer

Del

NOVALIQ GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the appointment of Gabriela Burian, MD, MPH, as NOVALIQ’s Chief Medical Officer (CMO).

Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading NOVALIQ’s global clinical development and regulatory efforts, as well as expanding the company’s proprietary ocular therapeutics pipeline. Dr. Burian has deep clinical knowledge and proven leadership in the areas of ophthalmic biomedical research and clinical translation, with specialized expertise in retina diseases. Previously, Dr. Burian held various leadership positions, including Global Program Medical Director at Novartis Pharma and Ophthalmology Early Program Leader at F. Hoffmann-La Roche. She founded and directs GB Biomed Advisors GmbH and serves as CMO for Iconic Therapeutics, Inc. She is a faculty member of the European School for Advanced Studies in Ophthalmology.

“NOVALIQ has a very exciting and robust dry eye therapy pipeline and has the potential to address significant clinical needs in retina and glaucoma as well,” said Dr. Burian. “With multiple pre-clinical and clinical stage programs in development, the company is strongly positioned to be a global leader in dry eye disease. My top priorities are to advance these programs toward regulatory submissions and to identify, develop and manage new drug development opportunities in glaucoma and retina diseases by harnessing the power of NOVALIQ’s proprietary EyeSol® technology, which enhances the topical bioavailability, stability and safety of traditionally insoluble or unstable drugs.”

Sonja Krösser, PhD, vice president of preclinical and clinical development will continue to lead NOVALIQ’s dry eye developments and remains responsible for the preclinical and clinical team. Dr. Krösser is a translational science and clinical development expert with more than 15 years in the biopharmaceutic industry and in-depth experience in dry eye disease. She was and will be instrumental in the advancement of NOVALIQ’s rich and differentiated dry eye product pipeline, which includes the CE-approved NovaTears®; NovaTears® Omega-3 a new preservative-free, multi-dose eye drop formulation expecting CE mark in 2017; CyclASol®, currently in Phase 2 clinical trials in the U.S.; and, the recently announced, first-in-class ocular pain and anti-inflammatory cannabinoid DED drug development program.

Dr. Burian will join NOVALIQ’s executive management team, reporting to the company’s managing director and CEO Christian Roesky, PhD. “I’m delighted to welcome Gabriela to NOVALIQ ,” said Dr. Roesky. “With Gabriela’s extensive experience leading medical and clinical development teams combined with Sonja’s demonstrated track record of advancing our dry eye pipeline, we are strengthening our mission to transform active pharmaceutical ingredients (APIs) into highly effective ocular therapeutics for both the front and the back of the eye.”

About NOVALIQ– NOVALIQ GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. NOVALIQ’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. NOVALIQ has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. NOVALIQ’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.

Contact information

NOVALIQ GmbH
For US:
Michael O’Rourke + 1 813 323 1438
Strategic Consultant
mrourke@novaliq.com
or
For EU/Asia:
Heidrun Kirsch + 49 6221 50259 243
VP Marketing
hkirsch@novaliq.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F24.4.2018 20:30Pressemelding

Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed its 2017 “Document de Référence” for the year ended December 31, 2017, including the management report and the annual financial report with the “Autorité des Marchés Financiers (AMF)” and its Annual Report on Form 20-F for the year ended December 31, 2017 with the U.S. Securities and Exchange Commission (SEC). These documents can be accessed on the Investors section of the Company’s corporate website (www.erytech.com). In addition, the “Document de Référence” is also available on the AMF’s website (http://www.amf-france.org) and the Annual Report on Form 20-F is also available on the SEC’s website (www.sec.gov). Printed copies of these documents are also

Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation24.4.2018 16:00Pressemelding

Rimini Street, Inc . (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced the first offerings in a family of solutions designed to provide improved competitive advantage to organizations with mature and valuable enterprise software investments that can be used as a foundation for innovation. Rimini Street’s new solutions can enable an organization to quickly and cost-effectively modernize their current enterprise software with the latest desired features and capabilities, future-proof their technical platforms against yet-unknown technology changes, and secure their systems against a constantly evolving threat environment. Rimini Street’s new solutions enable organizations to leverage their existing systems as a solid foundation for an innovative hybrid IT strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/

Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI24.4.2018 15:53Pressemelding

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that four scientific posters will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Meeting in Honolulu, HI (April 29-May 3). The variety of data to be presented reflects Novaliq’s dedication to science and clinical research. With the collection of posters, Novaliq will share clinical and pre-clinical data on its EyeSol® drug delivery technology and provide insights into the mode of action of its NOV03/NovaTears® water-free therapy for the treatment of dry eye disease (DED). Furthermore, Novaliq will present its first pre-clinical efficacy data in glaucoma. Scientific posters supported by Novaliq will include: “Influence of perfluorohexyloctane containing eye drops on tear film thickness in patients with mild to moderate dry eye disease.” Authors: Garhöfer G., Schm

Temasys Communications and Appian Partner to Power Real-Time Communications in the Contact Center24.4.2018 15:00Pressemelding

Temasys Communications announced today that Appian has integrated with the Temasys Skylink technology, enabling real-time communications, including chat and co-browsing, in Appian’s new Intelligent Contact Center (ICC) Platform. “For our contact center customers, omni-channel communications are essential. Appian is working with Temasys to provide contact centers with real-time communication channels such as chat and co-browsing via the Temasys versatile SDKs,” said Arturo Oliver, Senior Director of Product Strategy at Appian. Temasys Skylink APIs will be compatible with the Appian Intelligent Contact Center Platform, making it easy for Appian customers to add real-time communication to their applications, including chat, voice, video and co-browsing. These integrations enable users to visit a website, begin a chat session that seamlessly escalates to a voice call and extend to co-browsing — all without changing apps or establishing a new connection. “We’re thrilled to work with Appian

PPG Reports Sustainability Progress, New 2025 Goals24.4.2018 13:07Pressemelding

PPG (NYSE:PPG) today released its 2017 Corporate Sustainability Report, which details the company’s continued progress in strengthening its sustainable operations in 2017 and the launch of new, aggressive sustainability goals it aims to achieve by 2025. The report is available at sustainability.ppg.com. “PPG’s sustainability efforts go beyond product innovations to extend to our customers’ operations and the communities in which we operate,” said Mark Cancilla, PPG vice president, environment, health and safety. “We are encouraged by our progress in 2017 and excited about our new goals, which are representative of the challenges and opportunities of our current business portfolio.” The company achieved the following progress in 2017: 32 percent of sales from products that provide customers with a sustainable advantage, an increase of 60 percent since 2012. This includes the unveiling of multiple products that provide a sustainable solution, such as Sigma Air Pure, a revolutionary bio-b

Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries24.4.2018 12:17Pressemelding

Bioiberica's combination of chondroitin sulphate and glucosamine hydrochloride, a slow action drug to treat osteoarthritis symptoms, was approved as an ethical drug in France, Austria, Hungary, Poland, and Finland through a mutual recognition process from Spain. ‘This approval confirms that Drug Agencies from different countries attest to the effectiveness and safety of the combination of pharmaceutical grade chondroitin sulphate and glucosamine hydrochloride. This drug has proven to reduce pain and improve mobility in people affected by knee osteoarthritis which, due to its safety profile, could also be used as an alternative by those patients with cardiovascular or gastrointestinal problems who should not be prescribed anti-inflammatory drugs chronically’, stated Dr Juan Gispert, Bioiberica's R&D director. The principle study that guarantees its effectiveness is the MOVES clinical trial, published in the Annals of the Rheumatic Diseases, which concludes that the combination of chondr